Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Temporal Interference Transcranial Alternating Current Stimulation Targeting the BNST or Amygdala for Generalized Anxiety Disorder (TIs-GAD)

16 de novembro de 2026 atualizado por: Yumeng Ju, Central South University

Temporal Interference Transcranial Alternating Current Stimulation Targeting the BNST or Amygdala for Generalized Anxiety Disorder: A Randomized Controlled Trial

This randomized controlled trial will use a three-arm, parallel-group design to evaluate the efficacy and safety of 5-Hz Temporal Interference transcranial Alternating Current Stimulation (TI-tACS) in adults with generalized anxiety disorder (GAD). A total of 75 participants will be randomized in a 1:1:1 ratio to receive stimulation targeting the right bed nucleus of the stria terminalis (BNST), stimulation targeting the right amygdala, or sham stimulation. Participants will receive three 20-minute sessions per day, with 1-hour intervals between sessions, for 7 consecutive days (21 sessions in total). The primary outcome is the change in Hamilton Anxiety Rating Scale (HAMA) total score from baseline to Week 1. Secondary and exploratory assessments will include clinical symptoms, intolerance of uncertainty and related cognitive characteristics, treatment tolerability, adverse events, and EEG and MRI measures. Follow-up assessments will be conducted at Week 1, Week 4, and Week 8 from baseline to assess the durability of clinical effects and safety.

Visão geral do estudo

Descrição detalhada

Generalized anxiety disorder (GAD) is characterized by persistent and excessive anxiety and worry. Intolerance of uncertainty is an important cognitive feature associated with pathological worry. The amygdala and bed nucleus of the stria terminalis (BNST) contribute to threat processing, with evidence suggesting differences in their responses to brief and sustained threats. Comparing interventions targeting these regions may help clarify their contributions to anxiety symptoms, intolerance of uncertainty, and persistent worry.

Temporal interference stimulation uses two kilohertz-frequency alternating currents with a small frequency difference to generate an amplitude-modulated electric field envelope at the difference frequency. This study will compare right BNST-targeted and right amygdala-targeted stimulation using a 5-Hz envelope, with sham stimulation as the control.

Individualized head models will be constructed from each participant's T1-weighted magnetic resonance images. Electric field modeling will guide scalp electrode placement for the assigned target. Stimulation intensity will be individually adjusted according to participant tolerability within a range of 1.5-3.5 mA per channel, expressed as zero-to-peak amplitude.

Electroencephalography and magnetic resonance imaging will be used to investigate changes in theta-band activity and functional connectivity within anxiety-related networks. Associations between these changes and improvements in clinical symptoms and cognitive measures will be examined to explore the neural mechanisms of stimulation at the two targets. Peripheral blood samples will be collected at baseline, Week 1, and Week 8 and stored for future exploratory biomarker analyses related to GAD and treatment response.

Tipo de estudo

Intervencional

Inscrição (Estimado)

75

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • Fujian
      • Fuzhou, Fujian, China
        • Recrutamento
        • Neuropsychiatric Prevention and Treatment Hospital of Fuzhou Second General Hospital
        • Contato:
    • Hunan
      • Changsha, Hunan, China
        • Recrutamento
        • Second Xiangya Hospital of Central South University
        • Contato:
      • Changsha, Hunan, China
        • Ainda não está recrutando
        • Brain Hospital of Hunan Province (Hunan Second People's Hospital)
        • Contato:
    • Jiangsu
      • Yangzhou, Jiangsu, China
        • Recrutamento
        • Jiangsu Yangzhou Wutaishan Hospital
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 55 anos (Adulto)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Aged 18 to 55 years, inclusive, of any sex;
  2. Diagnosis of generalized anxiety disorder (GAD) according to DSM-5 criteria, assessed by trained researchers using the Structured Clinical Interview for DSM-5 (SCID), without psychotic features;
  3. Hamilton Anxiety Rating Scale (HAMA) total score of 14 or higher at screening;
  4. Has completed at least junior high school education and has sufficient hearing, reading, writing, and comprehension abilities to complete study assessments;
  5. Is willing and able to provide written informed consent and comply with study visits, treatment procedures, laboratory tests, and other study requirements.

Exclusion Criteria:

  1. Participants with a current or previous diagnosis of a major psychiatric disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), such as schizophrenia spectrum and other psychotic disorders or bipolar and related disorders;
  2. Pregnancy or lactation;
  3. Neurologic disorders or serious systemic diseases (e.g., thyroid disease, lupus erythematosus, diabetes, hepatic or renal impairment, active infection, major trauma);
  4. History of significant head injury or coma;
  5. Received any standardized neuromodulation therapy targeting the nervous system within the past 6 months before enrollment, including but not limited to electroconvulsive therapy (ECT), deep brain stimulation (DBS), transcranial magnetic stimulation (TMS), or vagus nerve stimulation (VNS);
  6. Suspected or confirmed history of alcohol or substance dependence;
  7. Current severe suicidal ideation or recent suicide attempt;
  8. Current participation in another clinical trial or recent use of prohibited psychotropic medications;
  9. Positive urine drug screening or abnormal thyroid function tests;
  10. Contraindications to magnetic resonance imaging (MRI) or electroencephalography (EEG);
  11. Inability to provide fully informed consent.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Right BNST-targeted TI-tACS

Participants will receive 5-Hz temporal interference stimulation targeting the right bed nucleus of the stria terminalis (BNST), for 20 minutes per session, three sessions per day with 1-hour intervals, for 7 consecutive days, for a total of 21 sessions.

Temporal Interference Transcranial Alternating Current Stimulation (TI-tACS) is a non-invasive neuromodulation technique that generates an envelope field (particularly 5 Hz) in deep brain regions, particularly the right BNST, through the interaction of two currents (2000 Hz, 2005Hz).

Temporal Interference Transcranial Alternating Current Stimulation (TI-tACS) is a non-invasive neuromodulation technique that generates an envelope field (particularly 5 Hz) in deep brain regions, particularly the right Amygdala, through the interaction of two currents (2000 Hz, 2005Hz)

Experimental: Right Amygdala-targeted TI-tACS

Participants will receive 5-Hz temporal interference stimulation targeting the right amygdala, for 20 minutes per session, three sessions per day with 1-hour intervals, for 7 consecutive days, for a total of 21 sessions.

Temporal Interference Transcranial Alternating Current Stimulation (TI-tACS) is a non-invasive neuromodulation technique that generates an envelope field (particularly 5 Hz) in deep brain regions, particularly the right BNST, through the interaction of two currents (2000 Hz, 2005Hz).

Temporal Interference Transcranial Alternating Current Stimulation (TI-tACS) is a non-invasive neuromodulation technique that generates an envelope field (particularly 5 Hz) in deep brain regions, particularly the right Amygdala, through the interaction of two currents (2000 Hz, 2005Hz)

Comparador Falso: Sham TI-tACS

Participants will receive sham temporal interference stimulation, for 20 minutes per session, three sessions per day with 1-hour intervals, for 7 consecutive days, for a total of 21 sessions.

Sham Temporal Interference transcranial Alternating Current Stimulation will mimic the sensory experience of active stimulation without delivering effective current.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change in Hamilton Anxiety Rating Scale (HAMA) Total Score From Baseline to Week 1
Prazo: Baseline and Week 1

Anxiety severity will be evaluated using the Hamilton Anxiety Rating Scale (HAMA), a clinician-administered instrument comprising 14 items. Total scores range from 0 to 56, with higher scores indicating more severe anxiety symptoms. The outcome is the change in HAMA total score from baseline to Week 1.

Baseline and Week 1

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Clinical Response Rate
Prazo: Week 1, Week 4, and Week 8

Clinical response will be assessed using the Hamilton Anxiety Rating Scale (HAMA), a 14-item clinician-administered scale with a total score range of 0 to 56. Higher scores indicate greater anxiety symptom severity, which represents a worse outcome. Clinical response is defined as a reduction of at least 50% in HAMA total score compared with baseline.

Week 1, Week 4, and Week 8
Clinical Remission Rate
Prazo: Week 1, Week 4, and Week 8

Clinical remission will be assessed using the Hamilton Anxiety Rating Scale (HAMA), a 14-item clinician-administered scale with a total score range of 0 to 56. Higher scores indicate greater anxiety symptom severity, which represents a worse outcome. Clinical remission is defined as a HAMA total score of 7 or less at the corresponding assessment time point.

Week 1, Week 4, and Week 8
Change in Hamilton Anxiety Rating Scale (HAMA) Total Score
Prazo: Baseline, Week 1, Week 4, and Week 8

Anxiety severity will be evaluated using the Hamilton Anxiety Rating Scale (HAMA), a clinician-administered instrument comprising 14 items. Total scores range from 0 to 56, with higher scores indicating more severe anxiety symptoms. The outcome is the change in HAMA total score from baseline to each subsequent assessment time point.

Baseline, Week 1, Week 4, and Week 8
Change in 17-item Hamilton Depression Rating Scale (HAMD-17) Total Score
Prazo: Baseline, Week 1, Week 4, and Week 8

Depressive symptom severity will be assessed using the 17-item Hamilton Depression Rating Scale (HAMD-17), a clinician-administered scale with a total score range of 0 to 52. Higher scores indicate greater depressive symptom severity, which represents a worse outcome. The outcome will be calculated as the change in HAMD-17 total score from baseline to each post-baseline assessment time point.

Baseline, Week 1, Week 4, and Week 8
Change in Generalized Anxiety Disorder-7 (GAD-7) Score
Prazo: Baseline, Week 1, Week 4, and Week 8

Anxiety symptom severity will be assessed using the Generalized Anxiety Disorder-7 (GAD-7), a 7-item self-report questionnaire with a total score range of 0 to 21. Higher scores indicate greater anxiety symptom severity, which represents a worse outcome. The outcome will be calculated as the change in GAD-7 score from baseline to each post-baseline assessment time point.

Baseline, Week 1, Week 4, and Week 8
Change in Intolerance of Uncertainty Scale (IUS) Score
Prazo: Baseline, Week 1, Week 4, and Week 8

Intolerance of uncertainty will be assessed using the Intolerance of Uncertainty Scale (IUS), a 27-item self-report questionnaire with a total score range of 27 to 135. Higher scores indicate greater intolerance of uncertainty, which represents a worse outcome. The outcome will be calculated as the change in IUS total score from baseline to each post-baseline assessment time point.

Baseline, Week 1, Week 4, and Week 8
Change in Anxiety and Depression Visual Analogue Scale Scores
Prazo: Baseline, Day 1, Week 1, Week 4, and Week 8

Subjective anxiety and depression severity will be assessed using visual analogue scale ratings for anxiety and depression. Each visual analogue scale score ranges from 0 to 10, with higher scores indicating greater subjective symptom severity, which represents a worse outcome. The outcome will be calculated as the change in visual analogue scale scores from baseline to each post-baseline assessment time point

Baseline, Day 1, Week 1, Week 4, and Week 8
Treatment-Emergent Side Effects During the Intervention and Follow-up Period
Prazo: Week 1, Week 4, and Week 8

Treatment-emergent side effects will be assessed using a physical treatment side-effect assessment that records the presence, type, severity, and relationship to the study intervention of adverse events. This outcome will be summarized as the occurrence and severity of treatment-emergent side effects during the intervention and follow-up period; higher severity indicates a worse safety outcome.

Week 1, Week 4, and Week 8

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Change in EEG Theta-Band Power
Prazo: Baseline, Week 1, and Week 8

Brain electrophysiological activity will be assessed using electroencephalography (EEG). Theta-band power (4-8 Hz) will be assessed using EEG. The outcome will be calculated as the change in theta-band power from baseline to each post-baseline assessment.

Baseline, Week 1, and Week 8
Change in Right Amygdala Seed-Based Resting-State Functional Connectivity
Prazo: Baseline, Week 1, and Week 8

Resting-state functional magnetic resonance imaging (fMRI) will be used to assess functional connectivity between the right amygdala and other brain regions. Connectivity will be quantified using Fisher z-transformed Pearson correlation coefficients between regional blood oxygen level-dependent (BOLD) signal time series. Changes from baseline will be calculated at each post-baseline MRI assessment.

Baseline, Week 1, and Week 8
Change in Right BNST Seed-Based Resting-State Functional Connectivity
Prazo: Baseline, Week 1, and Week 8

Resting-state functional magnetic resonance imaging (fMRI) will be used to assess functional connectivity between the right bed nucleus of the stria terminalis (BNST) and other brain regions. Connectivity will be quantified using Fisher z-transformed Pearson correlation coefficients between regional blood oxygen level-dependent (BOLD) signal time series. Changes from baseline will be calculated at each post-baseline MRI assessment.

Baseline, Week 1, and Week 8
Blinding Integrity at the End of Treatment
Prazo: Week 1

Blinding integrity will be assessed using a brief questionnaire completed independently by participants and outcome assessors after the week 1 primary outcome assessment. Respondents will indicate whether they believe the participant received active stimulation, sham stimulation, or "do not know." They will also be asked to guess the specific treatment assignment: right BNST-targeted stimulation, right amygdala-targeted stimulation, sham stimulation, or "do not know." The reasons for their guesses will be recorded. The percentages of correct guesses, incorrect guesses, and "do not know" responses will be summarized by randomized group, separately for participants and outcome assessors. Actual treatment assignments will not be disclosed during this assessment.

Week 1

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Cadeira de estudo: Yan Zhang, PhD, Second Xiangya Hospital of Central South University
  • Investigador principal: Yumeng Ju, PhD, Second Xiangya Hospital of Central South University
  • Diretor de estudo: Jiawu Ji, PhD, Neuropsychiatric Prevention and Treatment Hospital of Fuzhou Second General Hospital

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

26 de outubro de 2026

Conclusão Primária (Estimado)

1 de março de 2027

Conclusão do estudo (Estimado)

30 de junho de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

15 de outubro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

26 de outubro de 2026

Primeira postagem (Real)

2 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

16 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Individual participant data will not be shared because the dataset includes sensitive neuroimaging and biological data that may compromise participant confidentiality.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever